Log in to search using one of your social media accounts:

 

Modified Venetoclax Dose Ramp-Up in Select High-Risk Patients with Chronic Lymphocytic Leukemia (CLL) with Progression after B-Cell Receptor Pathway Inhibitors (BCRi)
CLL patients who progress after BCRi can experience rapid progression after therapy discontinuation and have poor outcomes. The BCL-2 inhibitor venetoclax has demonstrated activity in these patients. Patients with high tumor burden and aggressive disease treated with standard 5-week venetoclax dose ramp-up, required to mitigate potential tumor lysis syndrome (TLS), may experience symptomatic disease progression during initial weeks of low-dose venetoclax. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Matthew Davids, Jeffrey Jones, Herbert Eradat, Maria Verdugo, Jalaja Potluri, Richard R. Furman Source Type: research

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial
Venetoclax in patients with relapsed/refractory del(17p) CLL resulted in an ORR of 79% (7% CR) at the initial analysis of the M13-982 trial (n=107). Subsequently, 51 patients were enrolled in a safety expansion cohort. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: William Wierda, Brenda Chyla, Barbara Eichhorst, Johannes Schetelig, Talha Munir, Peter Hillmen, John F. Seymour, Andrew W. Roberts, Steven Coutre, Wojciech Jurczak, Stephen P. Mulligan, Clemens-Martin Wendtner, Matthew Davids, Sebastian B öettcher, Elis Source Type: research

CLL and Fat Cells Utilize Similar Metabolic Pathways
It is assumed that chronic lymphocytic leukemia (CLL) cells originate from B-cells. Yet, unlike their normal counterparts which are resting cells, CLL cells do proliferate. What energy source CLL cells use and which metabolic pathway they recruit to support proliferation is unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Uri Rozovski, David Harris, Ping Li, Zhiming Liu, Preetesh Jain, Alessandra Ferrajoli, Jan Burger, Phillip Thompson, William Wierda, Michael Keating, Zeev Estrov Source Type: research

Tumor Debulking and Reduction in Risk of Tumor Lysis Syndrome with Single-Agent Ibrutinib
Ibrutinib, a first-in-class, once-daily oral inhibitor of Bruton ’s tyrosine kinase, is approved for patients with CLL. Ibrutinib rapidly reduces lymphadenopathy after the first 2-3 months of treatment. The BCL2 inhibitor venetoclax is approved for relapsed del17p CLL. Tumor lysis syndrome (TLS), a notable risk with venetoclax, is associated with increased bulk of disease. Initial lead-in with ibrutinib may convert those with high-risk TLS to lower risk if administered prior to venetoclax. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Thomas J. Kipps, William G. Wierda, John C. Byrd, Susan O ’Brien, Steven Coutre, Paul M. Barr, Richard R. Furman, Jan A. Burger, Don Stevens, Jeff Sharman, Paolo Ghia, Ian Flinn, Cathy Zhou, Joi Ninomoto, Danelle F. James, Constantine Tam Source Type: research

Chronic Lymphocytic Leukemia and Polycythemia Vera Concomitantly Diagnosed: Case Report
The coexistence of myeloproliferative neoplasm (MPN) with lymphoid neoplasm (LN) is relatively rare event and among reported single case associations, the most represented LN is chronic lymphocytic leukemia (CLL). It was believed, that the coincidence of the MPN-CLL is incidentally and stochastic until recently when Todsico et al. suggested that clinical co-occurrence of those two entities might by related to common molecular events since similar JAK2-STAT signaling pathways are activated in both neoplasms. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Irina Panovska-Stavridis, Aleksandar Eftimov, Marija Popovska-Labacevska, Sanja Trajkova, Martin Ivanovski, Aleskandra Pivkova-Veljanovska, Lidija Cevreska, Aleksandar Dimovski Source Type: research

Chromosomal Microarray Analysis of Cytogenetic Alterations in Familial Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western countries. Low incidence of the disease among Chinese and Japanese and a higher prevalence in first-degree relatives of CLL patients constitutes strong evidence of the influence of genetic factors on CLL pathogenesis. Population-based studies have shown that approximately 9% of patients report a family history of CLL and are recognized as: sporadic and "familial CLL". Clinical trials with multigenerational pedigrees of familial CLL have described that younger generations have an earlier age of onset of the disease than older generations, ...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jorge Pinto Neto, Cintia Mascarenhas, Ros ângela Andrade, Juliana Mazzeu, Rinaldo Pereira Source Type: research

Long-Term Follow-Up of De Novo Chronic Phase Chronic Myelogenous Leukemia Patients on Imatinib First-Line
Imatinib mesylate (IM) represents the gold standard treatment for (CP) CML since 15 years, however outcomes in the very long-term remain unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Vincent Alcazer, Pierre Sujobert, St éphanie Dulucq, Stéphane Morisset, Mohamad Sobh, François-Xavier Mahon, Gabriel Etienne, Franck-Emmanuel Nicolini Tags: Chronic Myeloid Leukemia Source Type: research

Diagnostic Utility of the Bone Marrow Core Biopsy in Chronic Myeloid Leukemia
The utility of bone marrow (BM) biopsy in diagnosing chronic myeloid leukemia (CML) has come into question in the setting of improving ancillary diagnostic modalities. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Juliana Hidalgo-Lopez, Andres Quesada, Wei Wang, Rashmi Kanagal-Shamanna, Shimin Hu, L. Jeffrey Medeiros, Jorge Cortes, Hagop Kantarjian, Carlos Bueso-Ramos Source Type: research

5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia
The ponatinib PACE trial (NCT01207440) enrolled patients with CML or Ph+ ALL resistant/intolerant to dasatinib or nilotinib, or with T315I. Here, we report 5-year outcomes in CP-CML patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jorge E. Cortes, Hagop M. Kantarjian, Javier Pinilla-Ibarz, Philipp D. le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Moshe Talpaz, Michele Baccarani, Michael W. Deininger, Andreas Hochhaus, Timothy P. Hughes, Neil P. Shah, Stephanie Lustg Source Type: research

Generic Imatinib Therapy among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice
Generic imatinib therapy is being globally considered due to cost considerations. However, evidence of its efficacy and safety in Middle Eastern clinical settings is scarce. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Omar Shahin, Abdalla Awidi, Salah Abbasi, Kamal Alrabi, Khalid Kheirallah Source Type: research

Effect of Dose Modifications on 5-Year Efficacy of Dasatinib and Imatinib in Newly Diagnosed Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) From DASISION
Dasatinib dose adjustments may be necessary to manage adverse events (AEs). Multiple dasatinib dosage strengths are available, allowing adjustments to be possible. In a 2-year retrospective analysis of DASISION (Jabbour ASH 2011), higher response rates were maintained for dasatinib versus imatinib and efficacy was not compromised due to dose modifications. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jorge E. Cortes, Andreas Hochhaus, Hagop Kantarjian, Fran çois Guilhot, Vamsi Kota, Timothy P. Hughes, Suresh Shelat, Oumar Sy, Elias Jabbour Source Type: research

The OMNI Patient Registry: A Prospective, Observational, Non-Interventional Registry to Evaluate Vascular Safety of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Ponatinib is an oral tyrosine kinase inhibitor (TKI) that potently inhibits BCR-ABL1 and is approved in the US for the treatment of patients with CML or Ph+ ALL for whom no other TKI is indicated, or those with the T315I mutation. Long-term follow up of the pivotal PACE study (NCT01207440) showed a higher cumulative incidence of vascular occlusive events (VOEs) than reported at the time of ponatinib approval. Dose reductions were therefore implemented within PACE to mitigate the risk of VOEs. The exposure-adjusted incidence of VOEs has not increased over time in PACE but was greater in patients with a history of risk facto...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Annette Stemhagen, Deyaa Adib, Stephanie Lustgarten, Lisa McGarry, Ruth du Moulin, Sergio Santillana Source Type: research

Number-Needed-To-Treat (NNT) and Cost of Responses Achieved in Tyrosine Kinase Inhibitor (TKI) Treatment of Refractory Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in the United States (US)
The emergence of targeted therapies with high efficacy in small patient populations has challenged decision-makers. Ponatinib, a 3rd-generation TKI, shows activity against all common BCR-ABL single mutants including the highly resistant T315I mutant, and offers superior responses to other TKI therapy in the treatment of TKI-refractory CP-CML with or without T315I.1 (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Moshe Y. Levy, Lisa McGarry, Sergio Iannazzo, Hui Huang, Silvia Chiroli Source Type: research

Establishing a National Network of Laboratories Using Next Generation Amplicon Deep Sequencing for BCR-ABL1 Kinase Domain Mutation Screening in Philadelphia Chromosome-Positive Leukemias: the ‘NEXT-IN-CML' Study
Small retrospective studies have suggested that NGS may have several advantages over Sanger sequencing for BCR-ABL1 KD domain mutation screening in Ph+ leukemia patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Simona Soverini, Caterina De Benedittis, Luana Bavaro, Margherita Martelli, Stefania Stella, Paolo Vigneri, Anna Serra, Francesca Carnuccio, Santa Errichiello, Sara Galimberti, Claudia Barat è, Francesca Lunghi, Fabio Ciceri, Alessandra Lurlo, Nicola Oro Source Type: research

Survival Outcomes in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Receiving Third- or Subsequent Line (3L) Treatment
PACE was a phase 2 single-arm trial of ponatinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in 449 highly-refractory patients with CML or Philadelphia-chromosome positive (Ph+) acute lymphocytic leukemia (ALL) or who had the BCR-ABL T315I mutation. Overall survival (OS) for 3L CP-CML patients in PACE (n=97) at 1, 2, 3 and 4 years was estimated to be 91%, 83%, 80%, and 79%, respectively. Expected survival for 3L CP-CML patients prior to the availability of ponatinib has not been documented. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Daniel R. Stellato, Lisa McGarry, Hui Huang, Shaina Hastings, Thomas E. Delea, Jeffrey H. Lipton Source Type: research

Association between Proteomic Profile and Molecular Response (MR) in Chronic Myeloid Leukemia (CML) Patients
Recent advances in mass spectrometry have allowed the investigation of proteomic modifications associated with solid tumors, hematological neoplasms and identification of therapy –related proteomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Nicola Sgherza, Vito Michele Garrisi, Massimo Breccia, Angela Iacobazzi, Nicola Cascavilla, Ines Abbate, Attilio Guarini Source Type: research

Five-Year Efficacy and Safety of Dasatinib and Imatinib by Baseline Comorbidity and Age in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) from DASISION
Comorbidities in patients with CML may influence treatment-related decisions and impact response and survival. Retrospective analysis of 1-year data from the phase 3 DASISION study reported that baseline comorbidity did not substantially impact outcomes in dasatinib- or imatinib-treated patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Michael J. Mauro, Jorge E. Cortes, Andreas Hochhaus, Neil P. Shah, Ehab L. Atallah, Mena Abaskharoun, Oumar Sy, Giuseppe Saglio Source Type: research

Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis
Nilotinib has shown better efficacy compared to imatinib, but it has been associated to a higher incidence of arterial thrombotic events (ATEs). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Mariella D'Adda, Fabio Stagno, Luciano Levato, Angelo Michele Carella, Bruno Martino, Mario Tiribelli, Giovanna Rege-Cambrin, Antonella Gozzini, Marzia Salvucci, Michele Cedrone, Elena Trabacchi, Em Source Type: research

ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
ENESTfreedom and ENESTop are evaluating TFR (ie, tyrosine kinase inhibitor [TKI] cessation without losing response) after frontline and second-line nilotinib, respectively. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jerald Radich, Fran çois-Xavier Mahon, Andreas Hochhaus, Timothy Hughes, Sikander Ailawadhi, Jeffrey Lipton, Prashanth Gopalakrishna, Rafik Fellague-Chebra, Weiping Deng, Sandip Acharya, Giuseppe Saglio Source Type: research

Oral Asciminib (ABL001) vs Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Received ≥ 2 Prior Tyrosine Kinase Inhibitors (TKIs): A Multicenter, Open-Label, Randomized, Phase 3 Study
TKIs are the standard of care for patients with CML-CP, but some patients are resistant to or intolerant of available TKI therapies. Asciminib (ABL001) is a new TKI that targets the myristoyl pocket of BCR-ABL1 and functions as a potent and selective allosteric inhibitor, in contrast to currently available TKIs (eg, imatinib, nilotinib, dasatinib, bosutinib, ponatinib, radotinib) that target the BCR-ABL1 adenosine triphosphate (ATP) binding site. Asciminib has a resistance mutation profile that differs from those of ATP binding –site TKIs (Wylie AA, et al. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Michael Mauro, Carla Boquimpani, Yosuke Minami, Delphine R éa, Charisse Kemp, Shu-Fang Hsu Schmitz, Prashanth Gopalakrishna, Andreas Hochhaus Source Type: research

Bosutinib (BOS) vs Imatinib (IM) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results from the BFORE Trial
BOS is a dual SRC/ABL tyrosine kinase inhibitor approved for adults with Philadelphia chromosome-positive (Ph+) CML resistant or intolerant to prior therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jorge Cortes, Carlo Gambacorti-Passerini, Michael Deininger, Michael Mauro, Charles Chuah, Dong Wook Kim, Laurence Reilly, Alison Jeynes-Ellis, Eric Leip, Nathalie Bardy-Bouxin, Andreas Hochhaus, Tim Br ümmendorf Source Type: research

BCR-ABL Fluctuation in Chronic Myeloid Leukemia (CML) Patients with Deep Molecular Response (MR): What is the Meaning of a Big Wave when You Test the Patients in Different Laboratories?
RQ-PCR sensibility variation and the lack of standardization may cause uncertainties in clinical management. Better comprehension of the clinical value of BCR-ABL transcripts variation in patients with deeper molecular responses (RM ≥4) during treatment is extremely important and may differ between medical centers. Discontinuation studies raise even more concern about this issue. Therefore, this study aims to correlate BCR-ABL fluctuations measured by RQ-PCR in patients using TKI with RM≥4 and to verify its impact on Major Molecular Response (MMR) loss, as well as other possible related factors. (Source: Clinical Lym...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Mariana Pinto, Guilherme Bosi, Tito Costa, Kamila Grokoski, Andrea Kramer, Marco Abkalil, Laura Fogliatto, Lucia Silla Source Type: research

Therapy with Lower Dose Dasatinib in Newly Diagnosed Early Chronic Phase-Chronic Myeloid Leukemia (CML-CP)
Dasatinib is a potent tyrosine kinase inhibitor (TKI) of BCR-ABL. It is currently approved for the treatment of all phases of CML. Approved dose in the chronic phase is 100mg daily. This is however associated with notable side effects mainly myelosuppression and pleural effusion, leading to dose reductions/interruptions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Kiran Naqvi, Jorge Cortes, Jeffrey Skinner, Elias Jabbour, Naveen Pemmaraju, Gautam Borthakur, Zeev Estrov, Prithviraj Bose, Philip Thompson, Hagop Kantarjian Source Type: research

What Happens to Refractory or Intolerant Chronic Myeloid Leukemia Patients without Access to Clinical Trials?
A great challenge to Chronic Myeloid Leukemia (CML) treatment is the management of refractory or intolerant patients to current TKI (imatinib, dasatinib and nilotinib). This special population usually can be included in clinical trials to have access to the new drugs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Guilherme Bosi, Laura Fogliatto, Mariana Pinto, Tito Costa, Kamila Grokoski, Marco Abkalil, Camila Bender, Lucia Silla Source Type: research

Initial Therapy of CML with Dose-Optimized Imatinib: A Single Institution Experience
We report here the efficacy and tolerability of dose-adjusted imatinib in an academic setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Aditi Choudhry, Richard Van Etten Source Type: research

Survival Outcomes in Tyrosine Kinase Inhibitor Refractory Patients in Chronic Phase CML: A Single Center Retrospective Analysis
Little is known regarding the long term outcomes of CML patients who fail to achieve early complete cytogenetic remission (CCyR) with tyrosine kinase inhibitors (TKIs) in terms of disease progression and survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Justin Shaya, Phillip Boonstra, Malathi Kandarpa, Moshe Talpaz Source Type: research

Haploidentical Stem Cell Transplantation for Relapsed-Refractory Hodgkin Lymphoma: A Multicentre Analysis
Hodgkin Lymphoma (HL) is a curable disease for most patients with standard treatment. However, patients with primarily refractory disease or relapsing after autologous stem cell tranplantation (ASCT) have poor prognosis. In this setting, reduced-intensity conditioning, allogeneic stem cell transplantation is a potentially curative approach, and, in the absence of an HLA-identical donor, haploidentical SCT (haplo-SCT) with posttransplant cyclophosphamide (PT-Cy) has been evaluated with favorable preliminary results. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Marcelo Lacerda, Celso Arrais Rodrigues, Andr é Domingues Pereira, Yana Novis, Marina Fonseca, Roberto Silva, Maria Cristina Macedo, Nelson Hamerschlak, Iracema Esteves, Jayr Schmidt Filho, Marina Nascimento, Vanderson Rocha Tags: Hodgkin Lymphoma Source Type: research

Incidence of Secondary Malignancies after Hodgkin Lymphoma Treatment in Lebanon
The number of patients with Hodgkin ’s lymphoma that are being cured and have long term remission is increasing exponentially with time, this is due to newer anti-neoplastic drugs and improved radiotherapy. On the other hand, these new treatments involve higher risks for the development of secondary malignancies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Marcel Massoud, Tarek Bou Assy, Riwa Sakr, Layale Rached, Fadi Nasr, Charbel Yazbeck, Fouad Kerbage, Georges Chahine Source Type: research

Is Interim Pet-CT Scan Influencing the Choice of Subsequent Therapy in Hodgkin ’s Lymphoma Patients in Lebanon?
In Hodgkin ’s lymphoma, Pet-CT scan has established itself as the functional imaging modality of choice when it comes to evaluation and guiding treatment decisions. However, it remains an expensive imaging technique and therefore the number of PET CTs is limited for each patient. Recent studies show that Int erim Pet-CT scan is gaining an important role as a predictor of survival and an influencer for treatment modifications. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Fouad Kerbage, Marcel Massoud, Elie Akoury, Layale Rached, Riwa Sakr, Georges Rameh, Fady Nasr, Georges Chahine Source Type: research

PET-CT Adapted Therapy for Advanced Hodgkin Lymphoma: A Systematic Review of the Literature
Hodgkins, PET-CT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Iuliana Vaxman, Irina Amitai, Ronit Gurion, Liat Vidal, Eldad Dann, Pia Raanani, Anat Gafter-Gvili Source Type: research

Therapy Related Myeloid Neoplasia in Hodgkin Lymphoma after Autologous Stem Cell Transplantation (ASCT) – A Case Report
Therapy-related myeloid neoplasms (t-MN) are recognized complications of ASCT in lymphoma patients, and a leading cause of nonrelapse-related mortality (NRM). Several studies have attempted to identify the risk factors associated with t-MN after ASCT in lymphoma patients; however, these studies are limited by their observational design and relatively small number of t-MN patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Aleksandra Pivkova Veljanovska, Borce Georgievski, Martin Ivanovski, Lidija Cevreska, Irina Panovska Stavridis Source Type: research

Lymphoma and Leukemia Burden in Russia 2014: Comparison with Nordic Countries and Possible Cancer Registration Quality Issues
Lymphoma, leukemia, incidence, mortality. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Polina Shilo, Anton Barchuk, IIya Zuzgin, Sergey Alexeev Source Type: research

Secondary Hodgkin Lymphoma and MDS after Paclitaxel-Carboplatin Treatment in a Patient with Small Cell Lung Cancer
The rapid development of new therapies that improve patients ’ quality of life and treat various diseases has led to occurrence of more complex adverse drug reactions. This is obvious in cancer therapy where adverse events are more often neglected by the clinicians because of the primary goal of cancer therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Marija Petrushevska, Irina Panovska Stavrdis, Gordana Petrusevska Source Type: research

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy
The mutational profile of classical Hodgkin Lymphoma (cHL) is poorly characterized, and the genetics and evolution of refractory disease is completely unknown. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Valeria Spina, Alessio Bruscaggin, Martina Di Trani, Maurizio Martini, Silvia Locatelli, Elisa Cupelli, Gabriela Forestieri, Adalgisa Condoluci, Annarosa Cuccaro, Alden Moccia, Anastasios Stathis, Clara Deambrogi, Fary Diop, Georg St üssi, Franco Cavalli Source Type: research

Single Institution Experience with Nivolumab in Treatment of Patients with Relapsed or Refractory Hodgkin ’s Lymphoma
Nivolumab, Hodgkin ’s lymphoma. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Barbora Ka šperová, Miriam Ladická, Ľuboš Drgoňa, Radoslav Greksák, Ivona Bizikova, Ladislav Fekete, Martin Rázus, Andrej Vranovský Source Type: research

Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin ’s Lymphoma: The Real World Experience of a Single Bone Marrow Transplant Center in Salvador/Bahia
Brentuximab vedotin (BV) was reported to be effective when used as consolidation after autologous transplantation in patients with high-risk Hodgkin ’s Lymphoma (HL). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Laryssa Arag ão, Ohana Bispo, Hugo Carvalho, Alex Silva, Vitor Souza, Lilian Carvalho, Tiago Freitas, Luciene Oliveira, Bruna Salvino, Marco Araujo, Suellen Simoes, Adriana Barretto, Alessandro Almeida, Simone Viana Source Type: research

Hodgkin ’s Disease and Paraproteinaemia
Paraproteinaemia is not normally associated with Hodgkin ’s disease (HD). Only few cases of HD occurring in association with monoclonal immunoglobulins have been described in the literature. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Hunan Julhakyan, Tatyana Moiseeva, Lyubov Al-Radi, Valentina Dvyrnik, Sergey Kravchenko, Alla Kovrigina, Andrey Sudarikov, Valeriy Savchenko Source Type: research

Incidence Patterns for Hodgkin Lymphoma in Armenia: A Population-Based Study
Hodgkin lymphoma (HL) accounts for approximately 10% of all lymphomas and approximately 0.6% of all cancers diagnosed in the developed world annually. In the United States there are around 8000 new cases yearly diagnosed. The disease is reported to be slightly more common in males. The information on incidence patterns of HL in developing countries is limited. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Jemma Arakelyan, Diana Andreasyan, Arevik Torosyan, Lilit Sargsyan, Lusine Hakobyan, Samvel Iskanyan, Sergey Mkhitaryan, Ruzanna Papyan, Samvel Bardakchyan, Liana Avetisyan, Armen Tananyan, Gevorg Tamamyan Source Type: research

Autologous Stem Cell Transplant in Refractory Relapsed Hodgkin's Lymphoma: More than 10 years of Institutional Experience
Hodgkin's lymphoma refractory relapse, Autologous transplant. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Lautaro Sardu Source Type: research

Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205)
Hodgkin lymphoma (HL) patients who have relapsed after autologous hematopoietic cell transplantation (HCT) and received nivolumab may achieve adequate disease control and be eligible for allogeneic (allo)-HCT. US Prescribing Information recommends monitoring for allo-HCT complications after nivolumab —eg, hyperacute graft-versus-host disease (GVHD), grade (G) 3–4 GVHD, steroid-requiring febrile syndrome (SRFS), and other immune-mediated reactions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Carmelo Carlo-Stella, Graham P. Collins, Philippe Armand, Pier Luigi Zinzani, Jonathon B. Cohen, Ahmad Halwani, Michael Millenson, Mariano Provencio, Eva Domingo Domenech, Lisa Giulino-Roth, Luca Castagna, Kazunobu Kato, Mihaela Popa McKiver, Anne Sumbul, Source Type: research

Lenalidomide Use as Part of Induction Chemotherapy Does Not Increase the Risk Of Peri-Transplant Venous Thromboembolic Events (VTE) in Patients Who Undergo Autologous Stem Cell Transplant for Multiple Myeloma
Lenalidomide (len) is approved for treatment in Multiple Myeloma (MM) Use of len has been associated with an increase in venous thrombotic events (VTE) and aspirin prophylaxis is recommended for pts who are on active treatment with len. Autologous stem cell transplant (ASCT) is used during the treatment of MM after initial induction therapy. The use of intravenous catheters and hospitalization increase the risk of VTE in peri-transplant period. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Naresh Bumma, Monica Peravali, Ghayathri Jeyakumar, Seongho Kim, Asif Alavi, Divaya Bhutani, Lois Ayash, Voravit Ratanatharathorn, Joseph Uberti, Abhinav Deol Tags: Multiple Myeloma Source Type: research

The Correlation between CD44 and Atypical Monoclonal Proteins in Multiple Myeloma
Multiple Myeloma (MM) is a clonal disorder of plasma cells that originates in the bone marrow. Annual incidence of MM in Armenian population is 4 from 100000 people. Interleukin-6 (IL-6) is the major survival and growth factor for myeloma cells (MC). IL-6 promotes the proliferation of human MC and prevents apoptosis of it. However, IL-6 alone is not sufficient to ensure MC survival. It is dependent on many factors like different adhesion molecules such as the integrin family and CD44. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Aline Aywaz, Smbat Daghbashyan, Hasmik Dadayan, Narine Ghazaryan, Armine Pepanyan Source Type: research

Current Practices in Managing Multiple Myeloma (MM): Elucidating Educational Needs of Hematology/Oncology Clinicians
With the rapidly evolving treatment landscape, clinicians managing patients with MM base clinical judgment on their understanding and translation of clinical data into practice. Gaps in knowledge, competence, or confidence can impede implementation of best practices. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Linda M. Ritter, Sara R. Fagerlie, Irene M. Ghobrial, Ravi Vij, Patricia Repetto Source Type: research

Trial in Progress: Phase I Study of Actinium-225 (225Ac)-Lintuzumab in Patients with Refractory Multiple Myeloma
225Ac-lintuzumab is a radioimmunoconjugate composed of 225Ac (t ½=10 days), which emits 4 α-particles, linked to a humanized anti-CD33 monoclonal antibody. CD33 antigen is expressed on multiple myeloma (MM) plasmocytes in approximately 20% - 35% of MM patients and is a poor prognostic factor. Radioimmunotherapy with a particle-emitting constructs of the anti-C D33 monoclonal antibody lintuzumab has demonstrated safety and antileukemic effects in acute myeloid leukemia. Because it is targeting myeloid hematopoietic cells and malignant plasmocytes expressing CD33, 225Ac-lintuzumab may have less extramedullary to...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Moshe Yair Levy, Dragan Cicic, Greory Bergonio, Mark Berger Source Type: research

CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Antitumor immune responses in multiple myeloma (MM) may be suppressed through overexpression of the programmed death-1 (PD-1) receptor on effector cells and the PD-L1 ligand on myeloma cells (Liu et al, Blood 2007; G örgün et al, Clin Cancer Res 2015). Nivolumab, an anti–PD-1 monoclonal antibody (mAb), blocks PD-1 checkpoint signaling to enhance antitumor responses, and shows modest activity as monotherapy for relapsed/refractory (RR) MM (Lesokhin et al, J Clin Oncol 2016). Elotuzumab, an anti-SLAMF7 mAb, di rectly activates natural killer (NK) cells and mediates antibody-dependent cellular cytotoxicity. (S...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Sagar Lonial, Paul Richardson, Donna Reece, Hesham Mohamed, Suresh Shelat, Jes ús San Miguel Source Type: research

Single-Arm, Phase 2 Study of Elotuzumab in Combination With Pomalidomide and Dexamethasone in Patients With Multiple Myeloma Who Are Relapsed/Refractory to Lenalidomide: Initial Safety Data
In the Phase 3 ELOQUENT-2 trial, elotuzumab plus lenalidomide and dexamethasone (ELd) showed a 30% reduced risk of progression/death vs lenalidomide/dexamethasone and acceptable safety in patients (pts) with relapsed/refractory multiple myeloma (RRMM). However, therapies for pts refractory or intolerant to lenalidomide are needed. Pomalidomide has shown activity in lenalidomide-refractory pts and enhanced elotuzumab efficacy in a mouse model. Therefore, pomalidomide was combined with elotuzumab and dexamethasone (EPd) in this Phase 2 multicenter single-arm study (NCT02612779). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Sundar Jagannath, Jesus Berdeja, Robert Rifkin, Craig Cole, Michael A. Thompson, Rosanna J. Ricafort, Amanda Scofield, Hesham Mohamed, Oumar Sy, Ravi Vij, William Bensinger Source Type: research

Extramedullary Multiple Myeloma: Clinical Features and Prognosis in Argentina
Multiple myeloma is a heterogeneous disease. Up to one-third of patients may present extramedullary disease which is associated with a worse prognosis. Data from Latin America is scarce. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Cristian Seehaus, Natalia Schutz, Erika Brulc, Dorotea Fantl Source Type: research

Increased Semaphorin-4D and Plexin-B1 Levels in Multiple Myeloma Patients May Contribute to Osteolytic Bone Disease
During bone remodeling, semaphorin 4D (Sema4D) binds to its receptor plexin-B1, and the downstream molecular cascade ultimately modulates osteoblast motility. It has been suggested that multiple myeloma (MM) cells may utilize Sema4D to suppress osteoblast activity and bone formation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Ioannis Ntanasis-Stathopoulos, Evangelos Terpos, Tina Bagratuni, Dimitrios Christoulas, Maria Gavriatopoulou, Efstathios Kastritis, Meletios-Athanasios Dimopoulos Source Type: research

A Revised Staging System for Waldenstr öm's Macroglobulinemia
A significant proportion of patients with Waldenstr öm's Macroglobulinemia (WM) can survive for more than 10 years, but some patients die early during the course of the disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Maria Gavriatopoulou, Efstathios Kastritis, Marie Christine Kyrtsonis, Evdoxia Hatjiharissi, Eirini Katodritou, Panagiotis Repousis, Argiris Symeonidis, Michalis Michael, Anastasia Pouli, Nikolaos Giannakoulas, Dimitrios Christoulas, Aikaterini Megalakaki Source Type: research

Comparison of Peripheral Neuropathy Between the Original and a Generic Bortezomib in Multiple Myeloma Patients
Bortezomib has been the backbone of multiple myeloma treatment for more than 10 years, but its use in Brazil is very limited because of cost and reimbursement issues. The availability of generic bortezomib may increase the access of patients but the safety issues concern Brazilian health care professionals and patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Pedro Ivo Da Silva, Ana Carolina Figueiredo Modesto, Tatyana Xavier Almeida Matteucci Ferreira, Renato Sampaio Tavares, Danielle Le ão Cordeiro de Farias Source Type: research